NeuroSense Therapeutics Ltd.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Alon Ben-Noon
- Full Time Employees
- 17
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Building B Herzliya TA Israel 4672562
- IPO Date
- Dec 9, 2021
- CIK
- 0001875091
- Website
- neurosense-tx.com
- Similar Companies
- Business
- NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on the discovery and development of therapeutic treatments for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and Parkinson's disease. The company's core product is PrimeC, a novel extended-release oral formulation combining two FDA-approved drugs, ciprofloxacin and celecoxib, in a fixed-dose combination designed to target multiple pathogenic mechanisms in ALS, such as motor neuron degeneration, inflammation, iron accumulation, and impaired RNA regulation. NeuroSense also engages in research collaborations and clinical trials aimed at advancing therapeutic options for these complex diseases. NeuroSense operates primarily through clinical development activities, including pivotal Phase 3 trials for PrimeC in ALS across multinational sites. The company is actively advancing this clinical program following FDA clearance to initiate the Phase 3 trial as of late 2025. NeuroSense has also entered into a binding term sheet with a leading global pharmaceutical company to develop and commercialize PrimeC in key territories, reflecting a strategic partnership aimed at strengthening its financial, operational, and development capabilities. This alliance is pending finalization but signals a significant potential for milestone payments and royalty revenues. Founded in 2014, NeuroSense Therapeutics is headquartered in Israel and focuses on addressing the substantial unmet medical needs of patients with neurodegenerative disorders by developing combined therapies that modulate multiple disease pathways. The company maintains ongoing collaborative research efforts, including a precision medicine partnership with Genetika+ for Alzheimer's disease drug development. Recent developments include the completion of Phase 2b trials demonstrating PrimeC's efficacy in slowing ALS progression and improving survival rates significantly. The company continues to pursue regulatory and commercial pathways globally, emphasizing strategic partnerships and leveraging recent positive clinical data to propel its lead candidate toward market entry. NeuroSense Therapeutics' operations encompass research, clinical development, regulatory submissions, and strategic partnering within neurodegenerative disease markets primarily in North America, Europe, and other key international regions. Its research-driven approach and product pipeline position it as a notable entity in biotechnology targeting central nervous system disorders. This description incorporates the latest insights on NeuroSense's product offerings, clinical advances, strategic partnerships, and corporate focus as of December 2025.
Company News
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
NeuroSense Issues CEO Letter to Shareholders
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition
NeuroSense Announces Pricing of Insider-Led PIPE Financing
Brokerages Set NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Price Target at $8.50
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity